Takeda Signs an Exclusive License and Research Agreement with Debiopharm to Develop Novel Microbiome Therapeutics for the Gastrointestinal Disorders

 Takeda Signs an Exclusive License and Research Agreement with Debiopharm to Develop Novel Microbiome Therapeutics for the Gastrointestinal Disorders

Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks

Shots:

  • Takeda will screen & optimize compounds derived from Debiopharm’s Debio 1454M program to identify candidates for further development to treat IBD and other GI disorders
  • Takeda will pursue the development of a novel preclinical narrow spectrum microbiome remodeling program. The candidates will be evaluated for their effectiveness against specific disease-causing microorganisms while preserving the natural balance of the microbiota
  • The collaboration allows Debiopharm to boost its microbiome remodeling program. Additionally, Debiopharm has significantly expanded its antibiotic and microbiology pipeline with the launch of several discovery programs and initiates P-II study in bone and joint infections with afabicin (Debio 1450)

Click here to read full press release/ article | Ref: PRNewswire | Image: Takeda

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post